Premium
Progression after docetaxel‐based chemotherapy in androgen‐independent prostate cancer
Author(s) -
Sella Avishay,
Sternberg Cora,
Kovel Svetlana,
Yarom Nirit,
Skoneczna Iwona
Publication year - 2007
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2007.07037.x
Subject(s) - docetaxel , medicine , prostate cancer , chemotherapy , oncology , clinical significance , prostate specific antigen , cancer , soft tissue , tumor progression , urology , surgery
OBJECTIVE To assess the clinical pattern of progression and prostate‐specific antigen doubling time (PSA‐DT) after exposure to docetaxel‐based chemotherapy in patients with androgen‐independent prostate cancer (AIPC). PATIENTS AND METHODS Fifty‐five patients received docetaxel‐based chemotherapy; data were collected retrospectively from three different departments. Progression was known in 44 (79%) and the PSA‐DT was available in 33 patients. RESULTS Of the 29 patients with soft‐tissue and soft‐tissue plus bone metastases, 22 (76%) developed soft‐tissue progression. Among the 35 patients with bone and bone plus soft‐tissue metastases, 27 (77%) had osseous progression. There was no difference between the PSA‐DT at progression before and after docetaxel‐based therapy (mean 3.1 vs 2.7 months, P = 0.592, Student’s t ‐test.). However, the median (range) PSA‐DT at progression after docetaxel‐based therapy was 0.84 (0.3–4) months in patients with a PSA response, significantly shorter than the median of 3.1 (0.3–12) months of patients with no biochemical response ( P = 0.002, Student’s t ‐test). The PSA‐DT dynamics at progression had no effect on survival ( P = 0.63, log‐rank test). CONCLUSION The pattern of progression after docetaxel‐based chemotherapy is predominantly osseous in patient with bone metastases and mostly soft‐tissue in those with soft‐tissue disease. Progression after docetaxel‐based chemotherapy in AIPC does not modify the PSA‐DT before docetaxel. Evaluation of a larger population is needed to assess the clinical relevance of PSA dynamics after docetaxel therapy.